These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16611147)

  • 1. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis.
    Kim TS; Tasker AS
    Curr Top Med Chem; 2006; 6(4):355-60. PubMed ID: 16611147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors.
    Kim TS; Hague AB; Lee TI; Lian B; Tegley CM; Wang X; Burgess TL; Qian YX; Ross S; Tagari P; Lin CH; Mayeda C; Dao J; Jordan S; Mohr C; Cheetham J; Viswanadhan V; Tasker AS
    Bioorg Med Chem Lett; 2004 Jan; 14(1):87-90. PubMed ID: 14684304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of cathepsin K inhibitors for osteoporosis.
    Deaton DN; Tavares FX
    Curr Top Med Chem; 2005; 5(16):1639-75. PubMed ID: 16375747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
    Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
    Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
    Yasuda Y; Kaleta J; Brömme D
    Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents.
    Deaton DN; Kumar S
    Prog Med Chem; 2004; 42():245-375. PubMed ID: 15003723
    [No Abstract]   [Full Text] [Related]  

  • 8. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.
    Altmann E; Green J; Tintelnot-Blomley M
    Bioorg Med Chem Lett; 2003 Jun; 13(12):1997-2001. PubMed ID: 12781182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
    Stoch SA; Wagner JA
    Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin K inhibitors for osteoporosis and potential off-target effects.
    Brömme D; Lecaille F
    Expert Opin Investig Drugs; 2009 May; 18(5):585-600. PubMed ID: 19388876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
    Robichaud J; Black WC; Thérien M; Paquet J; Oballa RM; Bayly CI; McKay DJ; Wang Q; Isabel E; Léger S; Mellon C; Kimmel DB; Wesolowski G; Percival MD; Massé F; Desmarais S; Falgueyret JP; Crane SN
    J Med Chem; 2008 Oct; 51(20):6410-20. PubMed ID: 18811135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors.
    Altmann E; Renaud J; Green J; Farley D; Cutting B; Jahnke W
    J Med Chem; 2002 Jun; 45(12):2352-4. PubMed ID: 12036343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary amides as selective inhibitors of cathepsin K.
    Léger S; Bayly CI; Black WC; Desmarais S; Falgueyret JP; Massé F; Percival MD; Truchon JF
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4328-32. PubMed ID: 17544269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin K, osteoclastic resorption, and osteoporosis therapy.
    Zaidi M; Troen B; Moonga BS; Abe E
    J Bone Miner Res; 2001 Oct; 16(10):1747-9. PubMed ID: 11585336
    [No Abstract]   [Full Text] [Related]  

  • 15. Cathepsin K and the design of inhibitors of cathepsin K.
    Yamashita DS; Dodds RA
    Curr Pharm Des; 2000 Jan; 6(1):1-24. PubMed ID: 10637370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
    Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
    J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.
    Morley AD; Kenny PW; Burton B; Heald RA; Macfaul PA; Mullett J; Page K; Porres SS; Ribeiro LR; Smith P; Ward S; Wilkinson TJ
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1658-61. PubMed ID: 19231183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K.
    Marquis RW; Ru Y; Yamashita DS; Oh HJ; Yen J; Thompson SK; Carr TJ; Levy MA; Tomaszek TA; Ijames CF; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; D'Alessio KJ; McQueney MS; Veber DF
    Bioorg Med Chem; 1999 Apr; 7(4):581-8. PubMed ID: 10353637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the discovery of cathepsin K inhibitors on bone resorption.
    Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
    Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.